| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.085 | 0.2 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.2 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.2 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.2 |